Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

NAFLD

Predictive value of ALT levels for NASH and advanced fibrosis

Nature Reviews Gastroenterology & Hepatology volume 10, pages 510–511 (2013)Cite this article

Subjects

With expanding waistlines, the prevalence of NAFLD has burgeoned to become the leading cause of chronic liver disease in the USA. A subset of patients with NAFLD meet criteria for NASH with its inherent risk of progression to cirrhosis. Verma et al. addressed the utility of alanine aminotransferase levels for predicting NASH or advanced fibrosis to decide who would benefit from the definitive test of liver biopsy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Algorithm for performing liver biopsy in patients with NAFLD.

References

  1. Torres, D. M., Williams, C. D. & Harrison, S. A. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 10, 837–858 (2012).

    Article  PubMed  Google Scholar 

  2. Chalasani, N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142, 1592–1609 (2012).

    Article  PubMed  Google Scholar 

  3. Verma, S., Jensen, D., Hart, J. & Mohanty, S. R. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. http://dx.doi.org/10.1111/liv.12226.

  4. Amarapurka, D. N. et al. Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis. Ann. Hepatol. 5, 30–33 (2006).

    CAS  PubMed  Google Scholar 

  5. Williams, C. D. et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140, 124–131 (2011).

    Article  PubMed  Google Scholar 

  6. Francanzani, A. L. et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48, 792–798 (2008).

    Article  Google Scholar 

  7. Lee, J. Y. et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living donors in Korea: a review of 589 consecutive liver biopsies in a single center. J. Hepatol. 47, 239–244 (2007).

    Article  PubMed  Google Scholar 

  8. Schindhelm, R. K. et al. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab. Res. Rev. 22, 437–443 (2006).

    Article  CAS  PubMed  Google Scholar 

  9. Bedogni, G. et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 6, 33 (2006).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Hamaguchi, M. et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am. J. Gastroenterol. 102, 2708–2715 (2007).

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The view(s) expressed herein are those of the author(s) and do not reflect the official policy or position of San Antonio Military Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, Department of Defense or the U.S. Government.

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Department of Medicine, Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Bethesda, 20889-5600, MD, USA

    Dawn M. Torres

  2. Division of Gastroenterology, Department of Medicine, San Antonio Military Medical Center, 3551 Roger Brooke Drive #3600, Fort Sam Houston, 78234, TX, USA

    Stephen A. Harrison

Authors
  1. Dawn M. Torres
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen A. Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen A. Harrison.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Torres, D., Harrison, S. Predictive value of ALT levels for NASH and advanced fibrosis. Nat Rev Gastroenterol Hepatol 10, 510–511 (2013). https://doi.org/10.1038/nrgastro.2013.138

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2013.138

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing